Cogent Biosciences Announces $400M At-the-Market Offering

What Happened
Cogent Biosciences, Inc. (COGT) filed an 8‑K on August 10, 2026 to disclose a prospectus supplement under its automatic shelf registration (Form S‑3ASR, File No. 333-291384) for an at‑the‑market (ATM) offering of up to $400,000,000 of its common stock. The shares may be offered and sold from time to time through or to Guggenheim Securities, LLC, under a Sales Agreement originally entered May 6, 2022 and amended November 7, 2025. Gibson, Dunn & Crutcher LLP provided a legal opinion related to the offering (attached as Exhibit 5.1).

Key Details

• Prospectus supplement filed with the SEC on August 10, 2026 for up to $400,000,000 of common stock.
• Sales to be made at prevailing market prices in an “at‑the‑market” offering through Guggenheim Securities as sales agent or principal.
• Offering is made under the Company’s automatic shelf registration statement on Form S‑3ASR (filed Nov 7, 2025).
• Legal opinion from Gibson, Dunn & Crutcher LLP is included as an exhibit to the 8‑K.

Why It Matters
This filing gives Cogent the ability to raise capital flexibly and quickly by selling shares into the market as needed, up to the $400M cap. For investors, that means potential dilution depending on how many shares the company actually sells and at what prices; it also signals the company is preparing a financing tool to support operations or development programs. The sales are subject to market conditions and legal restrictions, and the 8‑K is not itself an offer to sell securities.